CA Patent

CA2295028A1 — Proliposome powders for inhalation stabilised by tocopherol

Assigned to AstraZeneca AB · Expires 1999-01-07 · 27y expired

What this patent protects

There is described a proliposome powder, said powder comprising discrete particles each comprising in a single phase (1) a biologically active component, (2) a stabilising proportion of tocopherol, and (3) a lipid or mixture of lipids having a phase transition temperature of belo…

USPTO Abstract

There is described a proliposome powder, said powder comprising discrete particles each comprising in a single phase (1) a biologically active component, (2) a stabilising proportion of tocopherol, and (3) a lipid or mixture of lipids having a phase transition temperature of below 37 ~C. Also described is a process for the preparation of, and the pharmaceutical use of, the powder.

Drugs covered by this patent

Patent Metadata

Patent number
CA2295028A1
Jurisdiction
CA
Classification
—
Expires
1999-01-07
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.